Consuming large amounts of ultra-processed foods (UPF) — products high in additives, artificial ingredients, and extensive processing — is associated…
Articles by Andrea Lobo, PhD
Increasing blood vitamin D levels with high-dose supplementation can significantly reduce the risk of new disease activity in people…
People with multiple sclerosis (MS) seem to experience significant changes in cognition more than a year before significant physical…
The 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the world’s largest congress…
Children and adolescents who go on to develop multiple sclerosis (MS) begin visiting the emergency department more often than…
TG Therapeutics has started enrolling participants in a Phase 3 trial to test a new version of Briumvi…
Health Canada is warning that glatiramer acetate products, used in the country to treat relapsing-remitting multiple sclerosis (MS), may cause…
The United Arab Emirates became the first country to approve tolebrutinib, clearing it to treat adults with nonrelapsing…
A generic version of Ampyra (dalfampridine), used to improve walking in adults with multiple sclerosis (MS), is now…
Having better physical performance is associated with higher cognitive function in people with multiple sclerosis (MS), particularly among those…
Switching between CD20-targeting antibodies Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) doesn’t affect either’s effectiveness at lowering disease activity and…
Three self-reported prevalent symptoms among people with multiple sclerosis (MS) – fatigue, mobility issues, and cognitive impairment – are…
A research project to explore the genetic connection between the Epstein-Barr virus (EBV) and the risk of developing multiple…
Autologous hematopoietic stem cell transplant (aHSCT) could slow disease progression in people with relapsing-remitting multiple sclerosis (RRMS), according to…
About 62% of multiple sclerosis (MS) patients use disease-modifying therapies (DMTs) before and during pregnancy, and the medications…
A person’s total number of visits to multiple sclerosis (MS) clinics is not associated with a lower risk of…
Blood levels of a protein called GFAP, which reflects the activation and damage to support cells in the brain and…
Mitochondrial abnormalities, or problems in the powerhouses of cells, seem to be a main contributor to the death of important…
A multicenter Phase 2a clinical trial testing foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS) has…
Aetna Healthcare has agreed to reimburse Helius Medical Technologies’ PoNS device, short for Portable Neuromodulation Stimulator, which uses electrical…
Four Canadian nurses are among the 11 recipients of this year’s International Nightingale Awards, which support innovative projects aimed…
Ocrevus (ocrelizumab) appears to be safe and effective for children and adolescents with multiple sclerosis (MS), according to…
Wandercraft has launched Walk in New York, a new rehabilitation center that offers access to its advanced mobility…
The Multiple Sclerosis Association of America (MSAA) will host its 11th annual Improving Lives Benefit on May 14…
While a four-month progressive resistance training program improved muscle strength in people with secondary progressive multiple sclerosis  (SPMS) in…
Intimacy and sexuality among people with multiple sclerosis (MS) will be the focus of this year’s Holistic Health and…
Medicaid coverage for people with multiple sclerosis (MS) in the U.S. is associated with worse disease outcomes — including more…
Kyverna Therapeutics’ CAR T-cell therapy candidate KYV-101 was deemed safe and well tolerated, and showed preliminary signs of efficacy,…
A multicenter Phase 2a clinical trial testing Tiziana Life Sciences’ foralumab nasal spray in people with nonactive secondary progressive…
Fampridine, which is approved to improve walking in people with multiple sclerosis (MS), and the disease-modifying therapy Ocrevus…